or Try an Advanced Search...

    Technical Analysis for INZY - Inozyme Pharma, Inc.

    Grade Last Price % Change Price Change
    F 4.41 -1.12% -0.05
    INZY closed down 1.12 percent on Monday, July 1, 2024, on approximately normal volume.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical INZY trend table...
    Date Alert Name Type % Chg
    Spinning Top Other 0.00%
    Death Cross Bearish -2.43%
    Inside Day Range Contraction -0.23%
    200 DMA Resistance Bearish -1.56%
    50 DMA Resistance Bearish -1.56%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -1.56%
    Gapped Up Strength -1.56%
    Pocket Pivot Bullish Swing Setup -0.90%
    NR7 Range Contraction -0.90%
    NR7-2 Range Contraction -0.90%
    Older End-of-Day Signals for INZY ...

       Recent Intraday Alerts

    Alert Time
    Down 2 % about 9 hours ago
    60 Minute Opening Range Breakdown about 9 hours ago
    Fell Below Previous Day's Low about 9 hours ago
    10 DMA Resistance about 10 hours ago
    Up 1% about 10 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    INZY Chart by TradingView
    Basic chart:

    Profile

    Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as in the early stages of development for calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biopharmaceutical Life Sciences Biology Disease Pharmacy Molecular Biology Specialty Drugs Genetic Diseases Rare Genetic Disease Rare Genetic Diseases Recombinant Dna

    Is INZY a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 30 Why Did Inozyme Pharma, Inc. (INZY) Get a Strong Buy Rating from Analysts?
    Jun 21 Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children’s Bone Health (ICCBH)
    May 30 Inozyme Pharma to Present at the Jefferies Global Healthcare Conference
    May 23 Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences
    May 8 Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference
    May 8 Inozyme Pharma GAAP EPS of -$0.38 beats by $0.02
    May 7 Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights
    May 3 Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    Apr 9 Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Apr 8 Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
    See more INZY news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 7.795
    52 Week Low 2.689
    Average Volume 402,624
    200-Day Moving Average 4.61
    50-Day Moving Average 4.60
    20-Day Moving Average 4.62
    10-Day Moving Average 4.45
    Average True Range 0.20
    RSI (14) 42.20
    ADX 12.12
    +DI 20.32
    -DI 23.55
    Chandelier Exit (Long, 3 ATRs) 4.48
    Chandelier Exit (Short, 3 ATRs) 4.85
    Upper Bollinger Bands 5.00
    Lower Bollinger Band 4.24
    Percent B (%b) 0.22
    BandWidth 16.30
    MACD Line -0.09
    MACD Signal Line -0.07
    MACD Histogram -0.0149
    Fundamentals Value
    Market Cap 272.36 Million
    Num Shares 61.8 Million
    EPS -1.44
    Price-to-Earnings (P/E) Ratio -3.06
    Price-to-Sales 0.00
    Price-to-Book 2.24
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 4.66
    Resistance 3 (R3) 4.66 4.59 4.62
    Resistance 2 (R2) 4.59 4.52 4.58 4.60
    Resistance 1 (R1) 4.50 4.48 4.46 4.49 4.59
    Pivot Point 4.42 4.42 4.40 4.42 4.42
    Support 1 (S1) 4.33 4.36 4.30 4.33 4.23
    Support 2 (S2) 4.26 4.32 4.25 4.22
    Support 3 (S3) 4.17 4.26 4.20
    Support 4 (S4) 4.16